Closing remarks

• Mark your calendar for the 7th Symposium
  November 14-15, 2024

• Please share your ideas – topics for next year!
Additional questions remain:

• Endorsement of AAP Bright Futures and USPSTF

• Autoantibody assays needs further improvement, standardization, and QI

• Additional value of the screening with approved intervention, e.g., teplizumab?

• Can genetic pre-screening lower the cost of screening?
  – How to prevent loss to follow up of at-risk children to logistics of tracking or low engagement

• The cost-benefit of screening and monitoring among adults? (~350,000 adults with pre-symptomatic T1D in the U.S.)
The symposium recording will be posted on the BDC website within 10 days or use this QR:
STOP T1D offers a comprehensive educational program for healthcare providers in the United States interested in type 1 diabetes screening programs.

This program was developed independently by the Barbara Davis Center for Diabetes and supported in part by an educational grant from Sanofi US.

Questions@STOPT1Dprogram.org
Screen TO Prevent Type 1 Diabetes

Objectives:

Facilitate large-scale T1D screening by addressing the needs of:

1. Children and adults who wish to be screened or request information about the screening.
2. Children and adults who have been identified as islet autoantibody positive and/or dysglycemic.
3. **Health care providers caring for screening-detected high-risk children or adults.**
4. Health care organizations, hospitals, or clinics interested in initiation of a screening program.
Thank you

Scientific Committee
Brigitte Frohnert
R. Brett McQueen
Cristy Geno Rasmussen
Kimber Simmons
Janet Snell-Bergeon
Marisa Stahl
Andrea Steck

AMC IT Team
Michael Effler
Jeff Largen
Noah Dodero
Lisbel Woods
Daniel Felipe-Morales

Christy Vasey & Josh Hartz
Allison Reeds